Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1989 Apr;96(4):977–985. doi: 10.1111/j.1476-5381.1989.tb11910.x

A comparison of the effects of a series of anti-anginal agents in a novel canine model of transient myocardial ischaemia.

M C Allely 1, B J Alps 1
PMCID: PMC1854441  PMID: 2743088

Abstract

1. An anaesthetized canine model of transient myocardial ischemia (TMI) has been developed in which reproducible and reversible electrocardiographic (ECG) and haemodynamic responses are exacerbated by electrical pacing. 2. The model could separate the ECG and haemodynamic effects of compounds with anti-ischaemic properties. 3. Compounds known to possess peripheral or coronary vasodilator properties did not necessarily alleviate the ECG consequences of TMI since glyceryl trinitrate was active whereas dipyridamole was not. The effects of verapamil were complicated by its adverse conduction effects while lidoflazine inhibited the ECG changes only during the ischaemic phase and the 'metabolic modulator' oxfenicine worsened the ECG response. 4. In a model considered to lack coronary reserve, improvements observed in the ischaemic ECG and global ventricular function were considered to result from a direct myocardial effect of the drugs examined rather than by a vascular influence. This was provided to the greatest degree by the Ca2+-entry blockers nifedipine and nicardipine, with flunarizine adopting an intermediate position.

Full text

PDF
985

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allely M. C., Alps B. J. The effects of the novel anti-anginal compound RS 43285 on myocardial conduction in the anaesthetized dog. Br J Pharmacol. 1988 Feb;93(2):375–382. doi: 10.1111/j.1476-5381.1988.tb11444.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alps B. J., Calder C., Wilson A. Nicardipine in models of myocardial infarction. Br J Clin Pharmacol. 1985;20 (Suppl 1):29S–49S. doi: 10.1111/j.1365-2125.1985.tb05142.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Becker L. C. Effect of nitroglycerin and dipyridamole on regional left ventricular blood flow during coronary artery occlusion. J Clin Invest. 1976 Dec;58(6):1287–1296. doi: 10.1172/JCI108584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bernstein V., Peretz D. I. Lidoflazine: a new drug in the treatment of angina pectoris. Curr Ther Res Clin Exp. 1972 Aug;14(8):483–495. [PubMed] [Google Scholar]
  5. Cohen M. V., Kirk E. S. Differential response of large and small coronary arteries to nitroglycerin and angiotensin. Autoregulation and tachyphylaxis. Circ Res. 1973 Oct;33(4):445–453. doi: 10.1161/01.res.33.4.445. [DOI] [PubMed] [Google Scholar]
  6. Drake-Holland A. J., Passingham J. E. The effect of Oxfenicine on cardiac carbohydrate metabolism in intact dogs. Basic Res Cardiol. 1983 Jan-Feb;78(1):19–27. doi: 10.1007/BF01923190. [DOI] [PubMed] [Google Scholar]
  7. Fazekas T., Kiss Z. Torsade de pointes ventricular tachycardia associated with lidoflazine therapy. Eur Heart J. 1984 Apr;5(4):343–343. doi: 10.1093/oxfordjournals.eurheartj.a061662. [DOI] [PubMed] [Google Scholar]
  8. Hanley S. P., Hampton J. R. Ventricular arrhythmias associated with lidoflazine: side-effects observed in a randomized trial. Eur Heart J. 1983 Dec;4(12):889–893. doi: 10.1093/oxfordjournals.eurheartj.a061417. [DOI] [PubMed] [Google Scholar]
  9. Higgins A. J., Morville M., Burges R. A., Blackburn K. J. Mechanism of action of oxfenicine on muscle metabolism. Biochem Biophys Res Commun. 1981 May 15;100(1):291–296. doi: 10.1016/s0006-291x(81)80095-2. [DOI] [PubMed] [Google Scholar]
  10. Himori N., Ono H., Taira N. Simultaneous assessment of effects of coronary vasodilators on the coronary blood flow and the myocardial contractility by using the blood-perfused canine papillary muscle. Jpn J Pharmacol. 1976 Aug;26(4):427–435. doi: 10.1254/jjp.26.427. [DOI] [PubMed] [Google Scholar]
  11. Lew W. Y., Ban-Hayashi E. Mechanisms of improving regional and global ventricular function by preload alterations during acute ischemia in the canine left ventricle. Circulation. 1985 Nov;72(5):1125–1134. doi: 10.1161/01.cir.72.5.1125. [DOI] [PubMed] [Google Scholar]
  12. Loeb H. S., Danoviz J., Miller A., Gunnar R. M. Effects of oral dipyridamole on coronary dynamics and myocardial metabolism at rest and during pacing-induced angina in patients with coronary artery disease. Am Heart J. 1983 Jun;105(6):906–910. doi: 10.1016/0002-8703(83)90388-5. [DOI] [PubMed] [Google Scholar]
  13. Rousseau M. F., Hanet C., Pardonge-Lavenne E., Van den Berghe G., Van Hoof F., Pouleur H. Changes in myocardial metabolism during therapy in patients with chronic stable angina: a comparison of long-term dosing with propranolol and nicardipine. Circulation. 1986 Jun;73(6):1270–1280. doi: 10.1161/01.cir.73.6.1270. [DOI] [PubMed] [Google Scholar]
  14. Sbar S., Schlant R. C. Dipyridamole in the treatment of angina pectoris. A double-blind evaluation. JAMA. 1967 Sep 11;201(11):865–867. [PubMed] [Google Scholar]
  15. Schaper W. K., Xhoneux R., Jageneau A. H., Janssen P. A. The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator. J Pharmacol Exp Ther. 1966 May;152(2):265–274. [PubMed] [Google Scholar]
  16. Szekeres L., Csik V., Udvary E. Nitroglycerin and dipyridamole on cardiac metabolism and dynamics in a new experimental model of angina pectoris. J Pharmacol Exp Ther. 1976 Jan;196(1):15–28. [PubMed] [Google Scholar]
  17. Szekeres L., Udvary E. Haemodynamic factors influencing myocardial ischaemia in a canine model of coronary artery stenosis: the effects of nitroglycerine. Br J Pharmacol. 1983 Jun;79(2):337–345. doi: 10.1111/j.1476-5381.1983.tb11006.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Van Nueten J. M., Wellens D. Tissue specificity of calcium-antagonistic properties of lidoflazine. Arch Int Pharmacodyn Ther. 1979 Dec;242(2):329–331. [PubMed] [Google Scholar]
  19. Warltier D. C., Meils C. M., Gross G. J., Brooks H. L. Blood flow in normal and acutely ischemic myocardium after verapamil, diltiazem and nisoldipine (Bay k 5552), a new dihydropyridine calcium antagonist. J Pharmacol Exp Ther. 1981 Jul;218(1):296–302. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES